HomeNON PROFITACC Cardiovascular Summit Virtual Details: Keynote by Anthony S. Fauci, MD.

ACC Cardiovascular Summit Virtual Details: Keynote by Anthony S. Fauci, MD.

January 28, 2021

ACC Cardiology’s Cardiovascular Summit Virtual will feature two days of live content on Feb. 12-13, 2021, including the Leadership Forum keynote speech delivered by National Institute of Allergy and Infectious Disease Director Anthony S. Fauci, MD.

Course director Bo Walpole, MD, FACC, and course co-directors Geoffrey Rose, MD, FACC, and Cathleen Biga, MSN, FACC, have invited leaders from across private, integrated and academic practices to create a course intended for all cardiovascular practices and the entire cardiovascular care team. The conference aims to provide strategies and tools that will advance the concepts of the Quadruple Aim—improved patient experience, care team well-being, smarter spending and better health outcomes—within the work environment. The course will also address the unprecedented change experienced within the health care system since the start of the COVID-19 pandemic through relevant live sessions and on-demand content.

Live Sessions Include:

  • Mobilizing and Operationalizing Rapid Change – Christopher Fussell, President, McChrystal Group – Friday, Feb. 12, 2021 at 8:30 a.m. ET
  • COVID-19: Public Health and Scientific Challenges – Anthony S. Fauci, MD, Director, NIAID – Friday, Feb. 12, 2021 at 12:10 p.m. ET
  • CV Care in Unusual Places: Delivering Value Beyond Bricks and Mortar – Saturday, Feb. 13, 2021 at 10:25 a.m. ET
  • Telehealth – Cool Accessory or Essential Component of Health Care Delivery – Saturday, Feb. 13, 2021 at 11:00 a.m. ET

The course will also feature on-demand content available beginning on Monday, Feb. 1, 2021, which will be available for three months.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy